Overview

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR)

Status:
Active, not recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

This is an open label, Phase 1b/2 study with multiple treatment arms evaluating the safety, tolerability, PK, and preliminary efficacy of rucaparib in combination with a second anticancer therapy in patients with an advanced/metastatic solid malignancy (Phase 1b), followed by evaluation of the combination in one or more specific patient populations in an expansion phase (Phase 2 cohorts).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Clovis Oncology, Inc.

Collaborators:

Gilead Sciences
Immunomedics, Inc.

Treatments:

Antineoplastic Agents
Camptothecin
Immunoconjugates
Rucaparib